Author:
Seow Jeffrey,Graham Carl,Merrick Blair,Acors Sam,Steel Kathyrn J.A.,Hemmings Oliver,O’Bryne Aoife,Kouphou Neophytos,Pickering Suzanne,Galao Rui Pedro,Betancor Gilberto,Wilson Harry D.,Signell Adrian W.,Winstone Helena,Kerridge Claire,Temperton Nigel,Snell Luke,Bisnauthsing Karen,Moore Amelia,Green Adrian,Martinez Lauren,Stokes Brielle,Honey Johanna,Izquierdo-Barras Alba,Arbane Gill,Patel Amita,O’Connell Lorcan,O’Hara Geraldine,MacMahon Eithne,Douthwaite Sam,Nebbia Gaia,Batra Rahul,Martinez-Nunez Rocio,Edgeworth Jonathan D.,Neil Stuart J.D.,Malim Michael H.,Doores Katie J
Abstract
AbstractAntibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ab responses will be maintained or whether they will provide protection from re-infection. Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the magnitude of the nAb response is dependent upon the disease severity, but this does not affect the kinetics of the nAb response. Declining nAb titres were observed during the follow up period. Whilst some individuals with high peak ID50 (>10,000) maintained titres >1,000 at >60 days POS, some with lower peak ID50 had titres approaching baseline within the follow up period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from Guy’s and St Thomas’ Hospitals. We suggest that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds. This study has important implications when considering widespread serological testing, Ab protection against re-infection with SARS-CoV-2 and the durability of vaccine protection.
Publisher
Cold Spring Harbor Laboratory